Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.



As discussed below in Item 5.07, Travere Therapeutics, Inc. (the "Company") held
its 2022 Annual Meeting of Stockholders (the "Annual Meeting") at which the
Company's stockholders approved the Company's 2018 Equity Incentive Plan, as
amended (the "2018 Plan"), to, among other items, increase the number of shares
of common stock authorized for issuance thereunder by 2,000,000 shares. A
summary of the material terms of the 2018 Plan is set forth in the Company's
definitive proxy statement for the Annual Meeting filed with the Securities and
Exchange Commission on April 4, 2022. That summary is qualified in its entirety
by reference to the text of the 2018 Plan, which is filed as Exhibit 99.1 hereto
and incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.



On May 11, 2022, the Company held the Annual Meeting. As of March 18, 2022, the
record date for the Annual Meeting, 63,509,077 shares of common stock were
outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting,
53,295,615 shares of common stock were present in person or represented by proxy
for the four proposals summarized below.

Proposal 1: Election of Directors



The Company's stockholders elected the ten persons listed below to serve until
the Company's 2022 Annual Meeting of Stockholders. The final voting results are
as follows:

                                  Votes For        Votes Withheld         Broker Non-Votes
    Roy D. Baynes, M.D., Ph.D.    50,142,410           552,835               2,600,370
    Suzanne Bruhn, Ph.D.          48,552,059          2,143,186              2,600,370
    Timothy Coughlin              49,736,109           959,136               2,600,370
    Eric Dube, Ph.D.              50,633,516           61,729                2,600,370
    Gary Lyons                    39,642,782         11,052,463              2,600,370
    Jeffrey Meckler               49,038,131          1,657,114              2,600,370
    John A. Orwin                 40,685,271         10,009,974              2,600,370
    Sandra Poole                  50,141,611           553,634               2,600,370
    Ron Squarer                   50,563,401           131,844               2,600,370
    Ruth Williams-Brinkley        50,034,673           660,572               2,600,370

Proposal 2: Approval of the Company's 2018 Equity Incentive Plan, as amended



The Company's stockholders approved the 2018 Plan, as amended, to, among other
items, increase the number of shares of common stock authorized for issuance
thereunder by 2,000,000. The final voting results are as follows:

                         Votes For                 48,632,223
                         Votes Against             2,061,537
                         Abstentions                 1,485
                         Broker Non-Votes          2,600,370

Proposal 3: Approval, on an advisory basis, of the compensation of the Company's named executive officers



The Company's stockholders approved, on an advisory basis, the compensation of
the Company's named executive officers. The final voting results are as follows:

                         Votes For                 34,854,828
                         Votes Against             15,838,930
                         Abstentions                 1,486
                         Broker Non-Votes          2,600,371

--------------------------------------------------------------------------------

Proposal 4: Ratification of the Selection of Independent Registered Public Accounting Firm



The Company's stockholders ratified the selection by the Audit Committee of BDO
USA, LLP as the Company's independent registered public accounting firm for the
fiscal year ending December 31, 2022. The final voting results are as follows:

                         Votes For                 53,272,291
                         Votes Against               21,931
                         Abstentions                 1,393
                         Broker Non-Votes              -


Item 9.01  Financial Statements and Exhibits.



(d)  Exhibits

  Exhibit No.          Description
      99.1               Travere Therapeutics, Inc. 2018 Equity Incentive Plan, as amended.
      104              Cover Page Interactive Data File (embedded within

the Inline XBRL document).

--------------------------------------------------------------------------------

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TRAVERE THERAPEUTICS, INC.

Dated: May 12, 2022                                                    By:

/s/ Elizabeth E. Reed

Name: Elizabeth E. Reed

Senior Vice President, General

Title: Counsel and Secretary

© Edgar Online, source Glimpses